Abstract:Purpose: Runt-related transcription factor 2 (RUNX2) also known as core-binding factor subunit alpha-1 belongs to the family of runt domain transcription factors. RUNX2 is essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. In the articular cartilage, RUNX2 regulates MMP13 expression and is involved in the pathophysiology of osteoarthritis (OA). However, transcriptional regulation mechanism of RUNX2 in articular chondrocytes is far from clear. RUNX2 has two major isoforms. Type II isoform is restricted to osseous cells and mature chondrocytes, and the transcription is initiated at the distal promoter P1. Importantly the RUNX2 P1 promoter has a fragment containing a 600bp of sequence upstream of the transcription start sufficient for promoter activity, with only a few CpG sites contained in this region. We hypothesized that methylation status at specific CpG sites in the RUNX2 P1 promoter predominantly regulate promoter activity and correlate with messenger RNA levels in human chondrocytes. Methods: The superficial and deep zone of cartilage from patients with a fracture of the neck of femur (NOF; n = 11) were used for isolation of non-OA/healthy chondrocytes, whereas cartilage pieces adjacent to weight-bearing areas of OA femoral heads (lacking surface zones) were harvested to obtain OA chondrocytes (n = 15). Gene expression levels and percentage methylation of CpG sites within the RUNX2 P1 promoter were quantified by qRT-PCR and bisulfite pyrosequencing. Isolated primary human chondrocyte samples (n = 6) were cultured for 5 weeks in 3 groups: (i) cultured without treatment (control culture) and (ii) cultured using 2 μM 5-azadeoxycytidine (5-aza-dC). The effect of CpG methylation on RUNX2 promoter activity was determined using a CpG-free vector. Furthermore, to determine the CpG sites critical for RUNX2 promoter activity, RUNX2 wild type promoter construct activity was compared against 4 vectors containing mutations at different CpG sites. Results: RUNX2 expression in OA and NOF deep chondrocytes were 34-fold (p < 0.01) and 79-fold (p < 0.01) higher compared to NOF superficial chondrocytes. OA chondrocytes displayed a 10%, 14%, 32% and 41% statistically significant (P<0.01) reduction in methylation status at the −720, −686, −336 and +17 CpG sites respectively, whereas NOF deep chondrocytes a 13% and 19% reduction at the -336 and +17 CpG sites. A significant negative correlation was observed between RUNX2 gene expression and the percentage methylation of the CpG sites in OA chondrocytes. MMP13 expression in OA chondrocytes was 27-fold and 89-fold higher than observed n NOF superficial and deep chondrocytes, respectively. A significant positive correlation was observed between RUNX2 and MMP13 gene expressions in OA chondrocytes. RUNX2 expression by chondrocytes cultured using 5-aza-dC was observed to be 3.3-fold higher than in control culture chondrocytes. Significantly, the percentage methylation of the CpG site located at −336-bp in 5-aza-dC culture was lower than observed in control culture (55% vs. 87%). In vitro DNA methylation was noted to decrease RUNX2 promoter activity. Point mutations (CG to TG) created at the −336 and +17 CpG sites resulted in a significant reduction in RUNX2 P1 promoter activity. Conclusions: The current studies show that the increased expression of MMP13 in human osteoarthritic chondrocytes is correlated with RUNX2 expression. Critically, we show, methylation status of specific CpG sites in the P1 promoter is a key regulator of RUNX2 expression in human chondrocytes. These studies show for the first time that the percentage methylation of specific CpG sites correlates with RUNX2 gene expression level in clinical OA samples. Furthermore, point mutations created at the −336 and +17 CpG sites resulted in a significant reduction in RUNX2 P1 promoter activity. These findings indicate that CpG sites located at −336 and +17 are crucial regulators of RUNX2 transcription and offer a putative target for pharmacological intervention in the treatment of OA.

DNA methylation of the RUNX2 P1 promoter mediates MMP13 transcription in chondrocytes

Runx2 Expression is Regulated by Methylation Status of Specific Cpg Sites in the P1 Promoter and Correlates with Mmp13 Expression in Human Osteoarthritic Chondrocytes

Searching Potential Transcription Factors Regulating Mmp13 Overexpression Via Promoter Cpg Methylation Status in Human Osteoarthritic Chondrocytes: A Microarray Screening

Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.

Activation of the P38/CREB/MMP 13 Axis is Associated with Osteoarthritis

Notch Signaling Regulates MMP-13 Expression Via Runx2 in Chondrocytes.

Association of Reduced Type IX Collagen Gene Expression in Human Osteoarthritic Chondrocytes with Epigenetic Silencing by DNA Hypermethylation.

1,25-Dihydroxyvitamin D3 Activates MMP13 Gene Expression in Chondrocytes Through P38 MARK Pathway.

Runx3 Regulates Chondrocyte Phenotype by Controlling Multiple Genes Involved in Chondrocyte Proliferation and Differentiation

MiR-539-3p Alleviates Apoptosis and Extracellular Matrix Degradation in Chondrocytes of Childhood-Onset Osteoarthritis by Targeting RUNX2

Two of four alternatively spliced isoforms of RUNX2 control osteocalcin gene expression in human osteoblast cells

Runx2 and Runx3 differentially regulate articular chondrocytes during surgically induced osteoarthritis development

Runx1 Up-Regulates Chondrocyte to Osteoblast Lineage Commitment and Promotes Bone Formation by Enhancing Both Chondrogenesis and Osteogenesis.

Inflammatory Microenvironment Promotes Extracellular Matrix Degradation of Chondrocytes Through ALKBH5-dependent Runx2 M6a Modification in the Pathogenesis of Osteoarthritis

MAP Kinase-Dependent RUNX2 Phosphorylation Is Necessary for Epigenetic Modification of Chromatin During Osteoblast Differentiation

Effect of the Interaction Between MiR-200b-3p and DNMT3A on Cartilage Cells of Osteoarthritis Patients.

Regulation of Matrix Metalloproteinase-13 by MIRNA-320 in Chondrogenesis and Osteoarthritis

DNMT and HDAC inhibitors modulate MMP-9-dependent H3 N-terminal tail proteolysis and osteoclastogenesis

STAT3 promotes a youthful epigenetic state in articular chondrocytes

FoxO3a cooperates with RUNX1 to promote chondrogenesis and terminal hypertrophic of the chondrogenic progenitor cells

LncRNA CTBP1-AS2 is upregulated in osteoarthritis and increases the methylation of miR-130a gene to inhibit chondrocyte proliferation